Full Text View
Tabular View
No Study Results Posted
Related Studies
Compare Conventional Colonosocpy to Endoscopic AFI, NBI for Dysplasia Detection for Ulcerative Colitis & Cholangitis
This study is currently recruiting participants.
Study NCT00587236   Information provided by Mayo Clinic
First Received: December 21, 2007   Last Updated: July 31, 2009   History of Changes

December 21, 2007
July 31, 2009
March 2006
December 2008   (final data collection date for primary outcome measure)
Compare the dysplasia detection rate between scope modalities and biopsy type; surveillance or targeted biopsies in CUC patients with concurrent PSC. [ Time Frame: Two years ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00587236 on ClinicalTrials.gov Archive Site
Assess the impact of patient related factors on the difference in dysplasia detection rate between while light colonoscopy and the AFI and NBI techniques in patients with CUC and concurrent PSC. [ Time Frame: Two years. ] [ Designated as safety issue: Yes ]
Same as current
 
Compare Conventional Colonosocpy to Endoscopic AFI, NBI for Dysplasia Detection for Ulcerative Colitis & Cholangitis
A Blinded Comparison of Conventional Colonoscopy to Endoscopic AFI and NBI for Dysplasia Detection in Patients With Ulcerative Colitis and Sclerosing Cholangitis or Known Colorectal Dysplasia or Cancer- A Pilot Clinical Study

This study is being done to:

To attempt to increase the detection of precancerous colon tissue in patients with chronic ulcerative colitis and primary sclerosing cholangitis;

To determine if an investigational scope that can look at the lining of the colon in different ways will help the doctor identify abnormal tissue in patients with chronic ulcerative colitis and concurrent primary sclerosing cholangitis; and

To determine if this investigational scope can accurately detect precancerous or cancerous tissue in patients with chronic ulcerative colitis that are known to have had cancerous or precancerous tissue in the past.

Patients with concurrent chronic ulcerative colitis and primary sclerosing cholangitis or patients with chronic ulcerative colitis and known colorectal dysplasia or cancer, presenting for surveillance colonoscopy will be recruited. After giving informed consent patients will then undergo colonoscopy in a segmental fashion. Colonoscopy with white light will be performed to the cecum and examination will be performed on withdrawal. First conventional white light will be used to examine the cecum and ascending colon and random biopsies will be obtained. All endoscopically apparent lesions will be biopsied separately. Immediately following will be examination of that segment of cecum and ascending colon under AFI first, then NBI with targeted biopsies of suspicious areas being taken. The AFI and NBI modality will be achieved by simply flipping a switch.. If necessary, washing of oozing blood from random biopsy sites will be performed., The remainder of the colon will be assessed in like fashion: transverse, descending and rectosigmoid. Because high definition endoscopy is the default modality, this will be in use throughout the procedure.

All lesions detected will be documented and biopsied for a maximum of four biopsies per suspicious lesion. Note will be taken of which modality resulted in visualization of the lesion. Data on the factors under study will be collected: i) disease type (CUC + PSC or CUC with known dysplasia), ii) Age, iii) Sex, iv) length of time with disease, v) extent of disease, vi) the interaction between iv and v will be collected. In addition, dysplasia yes/no will be established after biopsy histology is established and the modality under which abnormalities were observed will also be recorded.

 
Observational
Cohort, Prospective
  • Colitis, Ulcerative
  • Cholangitis, Sclerosing
 
  • Patients with chronic ulcerative colitis and concurrent primary sclerosing cholangitis.
  • Patients with chronic ulcerative colitis and known dysplasia or cancer.

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Recruiting
65
April 2009
December 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • patients requiring a clinically indicated surveillance colonoscopy
  • able to give informed written consent
  • history of chronic ulcerative colitis and colonic dysplasia/or cancer or primary sclerosing cholangitis

Exclusion Criteria:

  • patients with known colonic obstruction
  • INR ./= 2.5 or thrombocytopenia ,50,000
  • patients with clinically important cardiopulmonary disease who are unable to safely undergo prolonged conscious sedation
  • pregnancy
  • symptomatic coronary artery disease
Both
18 Years to 75 Years
No
Contact: Mary A Knipschield 507-266-3972 knipschield.mary@mayo.edu
Contact: Debbra K Stark 507-2661521 stark.debbra@mayo.edu
United States
 
NCT00587236
Diahann Seaman, M.D., Principal Investigator, Mayo Clinic Rochester (MCR)
5-06
Mayo Clinic
 
Study Director: Christopher J Gostout, MD Mayo Clinic, Rochester, MN
Mayo Clinic
July 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP